TABLE 2

Comparison of baseline and follow-up visits (delta)

ItemΔ totalΔ SEA and COPDΔ SEAp-value
Δ of lung function
 FVC % predicted8 (−2–18)6 (−1–16)12 (−2–23)0.216
 FEV1 % predicted11 (3–22)11 (5–18)15 (−3–23)0.637
 RV % predicted−10 (−23–6)−11 (−24–5)−10 (−22–12)0.472
 TLC % predicted0 (−6–7)−1 (−6–5)0 (−6–10)0.128
 eNO ppb−6 (−30–9)−3 (−25–10)−7 (−32–8)0.612
Δ of blood gases
PO2 mmHg1 (−4–8)−2 (−5–10)2 (−3–7)0.740
PCO2 mmHg1 (−1–2)0 (−1–1)1 (−1–3)0.229
Δ of laboratory
 Eosinophils 103·µL−1−6 (−10– −4)−6 (−10– −4)−6 (−12– −3)0.571
Δ of OCS therapy
 OCS dosage mg−5 (−11–0)−3 (−6–0)−5 (−20– −1)0.070
 OCS therapy, n (%)−9 (11)−3 (7)−6 (14)0.069#
Δ of quality-of-life scores
 QoL-VAS1 (0–3)0 (−1–3)2 (0–3)0.019
 ACT score4 (0–8)3 (0–6)6 (1–11)0.097
 Stair climbing (flights of stairs)0 (0–1)0 (0–1)0 (0–1)0.274
 Annual exacerbations, mean±sd−1.4±2.4−1.1±2.3−1.5±2.60.505
Δ of subjective condition, n (%)
 Worsened12 (14)4 (11)8 (22)0.453
 Stable41 (49)17 (47)16 (44)
 Improved31 (37)15 (42)12 (33)

Data are presented as median (interquartile range), unless otherwise stated. p-values were derived using t-test, if not indicated otherwise. SEA: severe eosinophilic asthma; FVC: forced vital capacity; FEV1: forced expiratory volume in 1 s; RV: residual volume; TLC: total lung capacity; eNO: exhaled nitric oxide; PO2: oxygen tension; PCO2: carbon dioxide tension; OCS: oral corticosteroids; QoL-VAS: quality of life visual analogue scale; ACT: asthma control test. #: Chi squared test; : Mann–Whitney U-test. Significant values are marked as bold.